Despite being implicated across the spectrum of cancer hallmarks, aberrant AXL signaling is just starting to emerge as a distinct anticancer target, with a growing focus on specific inhibitors as well as alternative novel drug designs.
Click to Enlarge
A Unique Receptor Family
Alterations in kinase genes are among the most common oncogenic events in cancer and thus present logical drug targets; approximately a quarter of ongoing drug development efforts involve kinase inhibitors.8
... to read the full story